CLOSURE Medical to Webcast First Quarter 2001 Conference Call

Apr 17, 2001, 01:00 ET from CLOSURE Medical Corporation

    RALEIGH, N.C., April 17 /PRNewswire/ -- CLOSURE Medical Corporation
 (Nasdaq: CLSR), a medical tissue adhesive products company, today announced
 that it intends to release, on Tuesday, April 24, 2001, financial results for
 the first quarter ended March 31, 2001.  In conjunction with this release
 CLOSURE will host a conference call that will be broadcast simultaneously live
 over the Internet.
     Individuals wishing to participate on the webcast, to be held at 4:30 PM
 EST on Tuesday, April 24, 2001, can access the event at http://www.vcall.com .
 Please allow extra time prior to the call to download the streaming media
 software required for listening to the Internet broadcast.  The online archive
 of the broadcast will be available within 2 hours of the live call and will be
 available for replay for 90 days.
     CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
 develops, manufactures, and commercializes medical tissue adhesive products
 based on its proprietary cyanoacrylate technology.  CLOSURE's nonabsorbable
 tissue adhesive products may be used to replace sutures and staples for
 certain topical wound closure applications, while its internal tissue adhesive
 products can potentially be used for internal wound closure and management.
 Currently marketed nonabsorbable tissue adhesive products include:
 DERMABOND(R) Topical Skin Adhesive, which is used to replace sutures and
 staples for closure of certain lacerations and incisions; SOOTHE-N-SEAL(TM)
 canker sore relief, an over-the-counter product to treat oral ulcers and mouth
 sores; and NEXABAND(R) topical adhesives used in veterinary wound closure and
 management.  The Company's LIQUIDERM(TM) liquid adhesive bandage has been
 approved by the FDA for the over-the-counter adhesive bandage market.
     DERMABOND(R) adhesive is a registered trademark of Ethicon, Inc.;
 SOOTHE-N-SEAL(TM) canker sore relief is a licensed trademark of Colgate Oral
 Pharmaceuticals, Inc.; LIQUIDERM(TM) adhesive is a trademark of CLOSURE
 Medical Corporation; and NEXABAND(R) adhesive is a registered trademark of
 CLOSURE Medical Corporation.
     To receive CLOSURE's latest news release and other corporate documents via
 fax, at no cost, call 1-800-PRO-INFO, use the Company's symbol CLSR.  Or visit
 the Financial Relations Board's website at www.frbinc.com .
     This release contains certain forward-looking statements which involve
 known and unknown risks, delays, uncertainties or other factors not under the
 Company's control which may cause actual results, performance or achievements
 of the Company to be materially different from the results, performance, or
 other expectations implied by these forward-looking statements.  These factors
 include, but are not limited to the early stage of commercialization of the
 Company products; the progress of its research and development programs for
 future products; the need for regulatory approval and effects of governmental
 regulation; technological uncertainties; the satisfactory conclusion of
 negotiations with, and dependence on marketing partners, and dependence on
 patents and trade secrets, as well as those detailed in the Company's Annual
 Report on Form 10-K for the year ended December 31, 2000 filed with the
 Securities and Exchange Commission.
 
 

SOURCE CLOSURE Medical Corporation
    RALEIGH, N.C., April 17 /PRNewswire/ -- CLOSURE Medical Corporation
 (Nasdaq: CLSR), a medical tissue adhesive products company, today announced
 that it intends to release, on Tuesday, April 24, 2001, financial results for
 the first quarter ended March 31, 2001.  In conjunction with this release
 CLOSURE will host a conference call that will be broadcast simultaneously live
 over the Internet.
     Individuals wishing to participate on the webcast, to be held at 4:30 PM
 EST on Tuesday, April 24, 2001, can access the event at http://www.vcall.com .
 Please allow extra time prior to the call to download the streaming media
 software required for listening to the Internet broadcast.  The online archive
 of the broadcast will be available within 2 hours of the live call and will be
 available for replay for 90 days.
     CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
 develops, manufactures, and commercializes medical tissue adhesive products
 based on its proprietary cyanoacrylate technology.  CLOSURE's nonabsorbable
 tissue adhesive products may be used to replace sutures and staples for
 certain topical wound closure applications, while its internal tissue adhesive
 products can potentially be used for internal wound closure and management.
 Currently marketed nonabsorbable tissue adhesive products include:
 DERMABOND(R) Topical Skin Adhesive, which is used to replace sutures and
 staples for closure of certain lacerations and incisions; SOOTHE-N-SEAL(TM)
 canker sore relief, an over-the-counter product to treat oral ulcers and mouth
 sores; and NEXABAND(R) topical adhesives used in veterinary wound closure and
 management.  The Company's LIQUIDERM(TM) liquid adhesive bandage has been
 approved by the FDA for the over-the-counter adhesive bandage market.
     DERMABOND(R) adhesive is a registered trademark of Ethicon, Inc.;
 SOOTHE-N-SEAL(TM) canker sore relief is a licensed trademark of Colgate Oral
 Pharmaceuticals, Inc.; LIQUIDERM(TM) adhesive is a trademark of CLOSURE
 Medical Corporation; and NEXABAND(R) adhesive is a registered trademark of
 CLOSURE Medical Corporation.
     To receive CLOSURE's latest news release and other corporate documents via
 fax, at no cost, call 1-800-PRO-INFO, use the Company's symbol CLSR.  Or visit
 the Financial Relations Board's website at www.frbinc.com .
     This release contains certain forward-looking statements which involve
 known and unknown risks, delays, uncertainties or other factors not under the
 Company's control which may cause actual results, performance or achievements
 of the Company to be materially different from the results, performance, or
 other expectations implied by these forward-looking statements.  These factors
 include, but are not limited to the early stage of commercialization of the
 Company products; the progress of its research and development programs for
 future products; the need for regulatory approval and effects of governmental
 regulation; technological uncertainties; the satisfactory conclusion of
 negotiations with, and dependence on marketing partners, and dependence on
 patents and trade secrets, as well as those detailed in the Company's Annual
 Report on Form 10-K for the year ended December 31, 2000 filed with the
 Securities and Exchange Commission.
 
 SOURCE  CLOSURE Medical Corporation